NasdaqGM:QTNT

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and sells products for the global transfusion diagnostics market in the United States, France, Japan, and internationally. More Details


Snowflake Analysis

Adequate balance sheet with limited growth.


Similar Companies

Share Price & News

How has Quotient's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: QTNT is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: QTNT's weekly volatility (9%) has been stable over the past year.


Market Performance


7 Day Return

6.1%

QTNT

-1.5%

US Medical Equipment

-0.9%

US Market


1 Year Return

-29.1%

QTNT

20.0%

US Medical Equipment

19.6%

US Market

Return vs Industry: QTNT underperformed the US Medical Equipment industry which returned 20.5% over the past year.

Return vs Market: QTNT underperformed the US Market which returned 21% over the past year.


Shareholder returns

QTNTIndustryMarket
7 Day6.1%-1.5%-0.9%
30 Day-13.1%4.9%3.0%
90 Day22.4%7.3%11.5%
1 Year-29.1%-29.1%21.0%20.0%22.3%19.6%
3 Year61.6%61.6%71.5%67.2%45.3%35.7%
5 Year-56.4%-56.4%167.2%147.2%124.8%99.9%

Long-Term Price Volatility Vs. Market

How volatile is Quotient's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Quotient undervalued compared to its fair value and its price relative to the market?

18.15x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate QTNT's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate QTNT's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: QTNT is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: QTNT is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate QTNT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: QTNT is overvalued based on its PB Ratio (18.2x) compared to the US Medical Equipment industry average (5x).


Next Steps

Future Growth

How is Quotient forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

20.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: QTNT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: QTNT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: QTNT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: QTNT's revenue (37.6% per year) is forecast to grow faster than the US market (10.2% per year).

High Growth Revenue: QTNT's revenue (37.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if QTNT's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Quotient performed over the past 5 years?

-16.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: QTNT is currently unprofitable.

Growing Profit Margin: QTNT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: QTNT is unprofitable, and losses have increased over the past 5 years at a rate of 16.5% per year.

Accelerating Growth: Unable to compare QTNT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: QTNT is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-0.3%).


Return on Equity

High ROE: QTNT has a negative Return on Equity (-274.74%), as it is currently unprofitable.


Next Steps

Financial Health

How is Quotient's financial position?


Financial Position Analysis

Short Term Liabilities: QTNT's short term assets ($195.9M) exceed its short term liabilities ($43.5M).

Long Term Liabilities: QTNT's short term assets ($195.9M) exceed its long term liabilities ($194.6M).


Debt to Equity History and Analysis

Debt Level: QTNT's debt to equity ratio (529.1%) is considered high.

Reducing Debt: QTNT's debt to equity ratio has increased from 441.4% to 529.1% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: QTNT has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: QTNT has sufficient cash runway for 2 years if free cash flow continues to reduce at historical rates of 7.8% each year.


Next Steps

Dividend

What is Quotient current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate QTNT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate QTNT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if QTNT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if QTNT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of QTNT's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.0yrs

Average management tenure


CEO

Franz Walt (61 yo)

2.83yrs

Tenure

US$2,290,335

Compensation

Mr. Franz Walt has been Chief Executive Officer of Quotient Limited since May 2018 and served as its Interim Chief Executive Officer from March 21, 2018 to May 2018. He has been Director at Quotient Limite...


CEO Compensation Analysis

Compensation vs Market: Franz's total compensation ($USD2.29M) is about average for companies of similar size in the US market ($USD2.38M).

Compensation vs Earnings: Franz's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Franz Walt
CEO & Director2.83yrsUS$2.29m0.38%
$ 2.3m
Peter Buhler
Chief Financial Officer0.92yrUS$897.86k0.0099%
$ 60.6k
Edward Farrell
Chief Operating Officer1yrUS$1.14m0.029%
$ 180.4k
Jeremy Stackawitz
Chief Commercial Officer2yrsUS$969.91k0.14%
$ 866.1k
Ernest Larnach
Head of Financial Accounting & Treasury1yrno data0.0090%
$ 54.9k

1.0yrs

Average Tenure

50yo

Average Age

Experienced Management: QTNT's management team is not considered experienced ( 1 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Franz Walt
CEO & Director2.83yrsUS$2.29m0.38%
$ 2.3m
Zubeen Shroff
Non-Employee Independent Director7.5yrsUS$176.00k0.061%
$ 371.4k
L. John Wilkerson
Independent Non-Employee Director8.92yrsUS$160.00k0.045%
$ 277.0k
Heino von Prondzynski
Independent Chairman of the Board2.83yrsUS$465.44k0.26%
$ 1.6m
Frederick Hallsworth
Independent Director9.92yrsUS$232.00k0.10%
$ 637.6k
Isabelle Buckle
Independent Director0.33yrno data0.0041%
$ 25.2k
Catherine Larue
Independent Director0.33yrno data0.0041%
$ 25.2k
Brian McDonough
Independent Director8.67yrsUS$220.00k0.10%
$ 610.6k

5.2yrs

Average Tenure

67yo

Average Age

Experienced Board: QTNT's board of directors are considered experienced (5.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 25.9%.


Top Shareholders

Company Information

Quotient Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Quotient Limited
  • Ticker: QTNT
  • Exchange: NasdaqGM
  • Founded: 2007
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$612.192m
  • Shares outstanding: 101.02m
  • Website: https://www.quotientbd.com

Number of Employees


Location

  • Quotient Limited
  • B1, Business Park Terre Bonne
  • Route de Crassier 13
  • Eysins
  • Vaud
  • 1262
  • Switzerland

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
QTNTNasdaqGM (Nasdaq Global Market)YesOrdinary SharesUSUSDMay 2014
U4WDB (Deutsche Boerse AG)YesOrdinary SharesDEEURMay 2014

Biography

Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and sells products for the global transfusion diagnostics market in the United States, France, Japan, and internationally. ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/15 23:32
End of Day Share Price2021/01/15 00:00
Earnings2020/09/30
Annual Earnings2020/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.